Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
about
Kinase profiling of liposarcomas using RNAi and drug screening assays identified druggable targets.Oncogenic Signaling Pathways in The Cancer Genome Atlas.Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.CDK4 inhibition diminishes p53 activation by MDM2 antagonistsPrevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic
P2860
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
@ast
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
@en
type
label
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
@ast
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
@en
prefLabel
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
@ast
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
@en
P2093
P2860
P1476
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
@en
P2093
Antoine Italiano
Audrey Laroche-Clary
François L Loarer
Marie-Alix Derieppe
Marie-Paule Algeo
Vanessa Chaire
P2860
P2888
P356
10.1186/S13045-017-0482-3
P577
2017-06-19T00:00:00Z
P6179
1086102545